AHR and breast cancer: Such a crosstalk through altered p300 recruitment to Nrf2-regulated target genes was shown, for e.g., in ER-positive MCF7 breast cancer cells treated with racemic sulforaphane, a dual AhR and ERα activator, 3,3′-diindolylmethane, and TCDD, or E2 [155].